DETERMINATION OF THE STABILITY OF A LOCAL ANESTHETIC BROMOKAIN TRANSDERMAL THERAPEUTIC SYSTEM

Aim. To study the stability of biocompatible microemulsion composition-based bromokain transdermal therapeutic systems (TTS) in order to confi rm the original shelf life and to identify the most appropriate TTS composition for storage.

Materials and methods. The stability test using accelerated aging method was performed on the samples of TTS containing 50 and 100 mg of bromokain. Physicochemical properties of TTS were analyzed at the end of the 1st, 2nd, 3rd, and 6th month of storage. The physical confi guration of the dosage form, the content of bromokain in TTS, and drug release were evaluated at each stage of the study. The content of bromokain in the samples was recorded using high performance liquid chromatography (HPLC). As a control for each method, the newly manufactured TTS forms were used.

Results. Unlike the samples containing 50 mg of bromokain, TTS with 100 mg of the anesthetic demonstrated changes in the physical confi guration and deterioration of the functional properties after the 6th month of storage. The quantitative content of the substance in TTS containing 50 and 100 mg of bromokain met the requirements of regulatory documentation (RD) at all
phases of the experiment and was within 50,0 ± 5,0 mg and 100,0 ± 10,0 mg, respectively. The release profi le of TTS with 50 mg of bromokain has remained unchanged during storage and complies with the RD. TTS with 100 mg of bromokain after the 3rd month of storage had a deviation from the release profi le indicated in the RD.

Conclusion. The shelf life of 2 years at t = 25 °C preset by us for samples of TTS containing 50 mg of bromokain has been confi rmed. According to the test results, samples of TTS with the content of bromokain of 100 mg were declared unstable and unfi t for storage under the selected storage conditions.

1. Мешковский АП. Испытания стабильности и установление сроков годности лекарственных препаратов. Фарматека. 2000; 2: 25–34. Meshkovskiy AP. Ispytaniya stabil'nosti i ustanovlenie srokov godnosti lekarstvennykh preparatov. Farmateka. 2000; 2: 25–34. [In Russ].

2. Государственная фармакопея РФ, XII издание (часть 1). М.: Научный центр экспертизы средств медицинского применения, 2008: 704. Gosudarstvennaya Farmakopeya RF, XII izdanie (chast' 1). M.: Nauchnyy tsentr ekspertizy sredstv meditsinskogo primeneniya, 2008: 704.

3. Отраслевой стандарт «Лекарственные средства. Порядок установления сроков годности» ОСТ 42-2-72. Министерство здравоохранения СССР. Министерство медицинской промышленности. 1972. Otraslevoy standart «Lekarstvennye sredstva. Poryadok ustanovleniya srokov godnosti». OST 42-2-72. Ministerstvo zdravookhraneniya SSSR. Ministerstvo meditsinskoy promyshlennosti, 1972.

4. Беликов ВГ. Фармацевтическая химия: учебн. пособие в 2 частях / В.Г. Беликов. 3-е изд. М.: МЕДпрессинформ, 2009: 616. Belikov VG. Farmatsevticheskaya khimiya uchebn. posobie v 2 ch. / V.G.Belikov. 3-e izd. M.: MEDpress-inform, 2009: 616.

5. Draft. Stability Testing of Active Pharmaceutical Ingredients and Pharmaceutical Products. WHO Working Document QAS/06.179/Rev.3, 2008.

6. Временная инструкция по проведению работ с целью определения сроков годности лекарственных средств на основе метода «ускоренного старения» при повышенной температуре (И-42-2-82). Министерство здравоохранения СССР. Министерство медицинской промышленности. 1983. Vremennaya instruktsiya po provedeniyu rabot s tsel'yu opredeleniya srokov godnosti lekarstvennykh sredstv na osnove metoda «uskorennogo stareniya» pri povyshennoy temperature (I-42-2-82). Ministerstvo zdravookhraneniya SSSR. Ministerstvo meditsinskoy promyshlennosti. 1983.

7. Скакаева ИВ, Бунатян НД, Ковалева ЕЛ, Саканян ЕИ, Митькина ЛИ, Прокопов ИА и др. Основные подходы к изучению стабильности лекарственных средств: отечественный и международный опыт. Ведомости Научного центра экспертзы средств медицинского применения. 2013; 3: 8–11. Skakaeva IV, Bunyatyan ND, Kovaleva EL, Sakanyan EI, Mit’kina LI,

8. Prokopov IA et al. Basic approaches drug stability studies: domestic and international experience. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya. 2013; 3: 8–11. [In Russ, English abstract].

9. Ryzhikova VA, Tikhobayeva AA, Salomatina LA, Kursakov SV, Kuznetsova EG, Kuryleva OM et al. Effect of the Transfer Activator on Functional Properties of the Bromocain Matrix Transdermal Therapeutic Systems. Inorganic Materials: Applied Research. 2014; 5 (5): 498–503. DOI: 10.1134/S2075113314050177 (translated from Perspektivnye Materialy, 2014; 2: 26–32).

10. Севастьянов ВИ, Саломатина ЛА, Кузнецова ЕГ, Собко ОМ, Шумаков ВИ. Матричные и резервуарные трансдермальные терапевтические системы инсулина на основе нетканых и полимерных материалов. Перспективные материалы. 2004; 4: 44–48. Sevast'yanov VI, Salomatina LA, Kuznetsova EG, Sobko OM, Shumakov VI. Matrix and reservoir transdermal therapeutic systems of insulin on nonwoven and polymeric substances base. Perspektivnye Materialy. 2004; 4: 44–48. [In Russ, English abstract].

11. Kuznetsova EG, Kuryleva OM, Salomatina LA, and Sevast'yanov VI. Matrix transdermal systems for caffeine delivery based on polymer and emulsion compounds. Biomed. Eng. 2008; 42: 141–144 (translated from Meditsinskaya Tekhnika. 2008; 42 (3): 33–35).

12. ГОСТ 29188.3-91 «Изделия косметические. Методы определения стабильности эмульсии». 1992. GOST 29188.3-91 «Izdeliya kosmeticheskie. Metody opredeleniya stabil'nosti emul'sii». 1992.